NCT02074267

Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Nang Kuang Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy of Gabapentin (Carbatin \& Neurontin) in patients with neuropathy pain.

Conditions

• Neuropathy
• Pain

Interventions

Type	Name	Description
DRUG	Carbatin	Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days. The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.
DRUG	Neurontin	Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days. The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.

Timeline

• Start date: 2009-03-01
• Primary completion: 2011-06-01
• Completion: 2011-09-01
• First posted: 2014-02-28
• Last updated: 2023-11-09

Locations

1 site across 1 country: Taiwan